No Data
No Data
Minsheng Health (301507.SZ): BASF (China) as a company's procurement supplier accounts for a relatively low proportion of the total annual procurement amount.
Minsheng Health (301507.SZ) stated on the investor interaction platform on September 12th that the company's raw material procurement, supply, product production, and sales are all normal. The company's products are mostly compound preparations, which generally require multiple raw materials. Fluctuations in the price of a single raw material have little impact on the overall cost of the company's products. BASF (China), as a procurement supplier of the company, accounts for a relatively low proportion of the total annual procurement amount. The company's inventory reserves are also relatively sufficient, and it will not have a significant impact on the company's production, operation, and annual performance.
Minsheng Health (301507.SZ) 21.3933 million restricted shares will be listed for trading on September 5th.
Minsheng Health (301507.SZ) announced that the number of shares released prior to the company's initial public offering to lift restrictions this time is...
People\'s Livelihood and Health: Summary of the 2024 Semi-Annual Report
People\'s Livelihood and Health: Semi-Annual Report 2024
Minsheng Health (301507.SZ): plans to launch a 3.5 million restricted stock incentive plan.
On August 28th, Gelonhui announced its restricted stock incentive plan for 2024. The plan intends to grant a total of 3.5 million shares of class 2 restricted stocks to the incentive recipients, accounting for approximately 0.98% of the company's total shares of 356.5543 million at the time of the plan announcement. The plan includes an initial grant of 3.32 million shares, accounting for 94.86% of the total equity to be granted, and 0.93% of the company's total shares at the time of the plan announcement. An additional 0.18 million shares are reserved, representing 5.14% of the total equity to be granted.
Minsheng Health (301507.SZ): net income of 77.2694 million yuan in the first half of the year, a year-on-year increase of 10.30%.
Geelonghui August 28th, Minsheng Health (301507.SZ) released the semi-annual report for 2024, with a report period revenue of 0.397 billion yuan, an 8.06% year-on-year increase; net income attributable to shareholders of the listed company was 77.2694 million yuan, a 10.30% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.5573 million yuan, a 14.42% year-on-year increase; basic earnings per share was 0.22 yuan.
No Data
No Data